CLOs on the Move

RTD Company

www.rtdco.com

 
RTD Company is a Andover, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.rtdco.com
  • 15825 Central Ave NE
    Andover, MN USA 55304
  • Phone: 763.689.4870

Executives

Name Title Contact Details

Similar Companies

Rubedo Life Sciences

Rubedo Life Sciences is an anti-aging company based in the Silicon Valley, California.

Ultivue

Ultivue develops innovative reagent-based solutions that maximize the biological information available from cells and tissue samples. The company`s technology is being used to elucidate biological pathways and to validate clinically-relevant biomarkers. Ultivue is based in Cambridge, MA. Our culture provides an exceptional work environment fostering innovation and collaboration to make a difference collectively. Ultivue`s employees are bright, flexible, and driven to create meaningful impact through our work. We work at a fast pace, but support each other achieve the work/life balance that helps us thrive as a company. Our entrepreneurial culture relies on contributions and input from all. Our bench of experienced managers provides mentoring and support to ensure front line staff make the most of their unique talents and energy.

BIOWEST THERAPEUTICS

BIOWEST THERAPEUTICS Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Linkage Inc

Linkage Inc is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.